Cogent Biosciences Inc (COGT)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Andrew R. Robbins
Employees:
80
200 CAMBRIDGE PARK DRIVE, SUITE 3100, CAMBRIDGE, MA 02140
617-945-5576

Cogent Biosciences, Inc. focuses on developing precision therapies for genetically defined diseases. Lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis.

Data derived from most recent annual or quarterly report
Market Cap 575.181 Million Shares Outstanding85.465 Million Avg 30-day Volume 1.054 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.64
Price to Revenue0.0 Debt to Equity0.0 EBITDA-187.302 Million
Price to Book Value3.4592 Operating Margin0.0 Enterprise Value587.318 Million
Current Ratio8.236 EPS Growth-0.144 Quick Ratio8.037
1 Yr BETA 1.3104 52-week High/Low 15.68 / 6.43 Profit Margin0.0
Operating Cash Flow Growth-26.3211 Free Cash Flow to Firm (FCFF) TTM -126.023 Million Free Cash Flow to Equity (FCFE) TTM
Altman Z-Score6.5229

Are you looking for this stock instead?

View SEC Filings from COGT instead.

View recent insider trading info

Cogent Biosciences Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding COGT (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding COGT

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-10-03 by ROS MATTHEW
  • 4: filed on 2023-07-05 by ROS MATTHEW
  • 4: filed on 2023-06-13 by FAIRMOUNT FUNDS MANAGEMENT LLC
  • 4: filed on 2023-06-08 by CAIN CHRISTOPHER W.
  • 4: filed on 2023-06-08 by SHEGOG TODD
  • 4: filed on 2023-06-08 by ROS MATTHEW
  • 4: filed on 2023-06-08 by HARWIN PETER EVAN
  • 4: filed on 2023-04-04 by ROS MATTHEW
  • 4: filed on 2023-02-15 by ROBINSON JOHN EDWARD
  • 4: filed on 2023-02-15 by KEARNS EVAN

    • Events (8k)

  • 8-K: filed on 2023-11-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-08:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-08:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-07:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-06:
    Item 8.01: Other Events
  • 8-K: filed on 2023-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-12-12:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    FERRANTE KAREN JEAN

    • Director
    		 0 2023-10-02 5

    ROS MATTHEW

    • Director
    		 0 2023-10-02 5

    FAIRMOUNT FUNDS MANAGEMENT LLC

    • 10% Owner
    • SEE REMARKS
    		 3,558,975 2023-06-09 1

    MORRIS ARLENE

    • Director
    		 0 2023-06-07 1

    HARWIN PETER EVAN

    • Director
    		 0 2023-06-07 1

    SHEGOG TODD

    • Director
    		 0 2023-06-07 1

    CAIN CHRISTOPHER W.

    • Director
    		 0 2023-06-07 1

    ROBBINS ANDREW R PRESIDENT AND CEO

    • Officer
    • Director
    		 0 2023-02-13 1

    GREEN JOHN L. CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-02-13 1

    KEARNS EVAN CHIEF LEGAL OFFICER

    • Officer
    		 0 2023-02-13 1

    SACHS JESSICA CHIEF MEDICAL OFFICER

    • Officer
    		 0 2023-02-13 1

    ROBINSON JOHN EDWARD CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2023-02-13 1

    VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P.

    VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P.

    VHCP CO-INVESTMENT HOLDINGS II, LLC

    VHCP CO-INVESTMENT HOLDINGS III, LLC

    VHCP MANAGEMENT II, LLC

    VHCP MANAGEMENT III, LLC

    KOH BONG Y

    SHAH NIMISH P

    • 10% Owner
    		 4,355,273 2020-08-14 0

    BOOTH BRUCE

    • Director
    		 0 2020-07-01 0

    ALDAG JORN

    • Director
    		 0 2020-07-01 0

    CAMPANA DARIO

    • 10% Owner
    		 No longer subject to file 2020-04-06 0

    ETTENBERG SETH CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2020-02-11 0

    HODGE GEOFFREY CHIEF TECHNICAL OFFICER

    • Officer
    		 0 2020-02-11 0

    OSBORNE MATTHEW SCOTT CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2020-02-11 0

    PEREZ ROBERT J

    • Director
    		 0 2019-06-14 0

    RATCLIFFE LIAM

    • Director
    		 0 2019-06-14 0

    VASCONCELLES MICHAEL CHIEF MEDICAL OFFICER

    • Officer
    		 0 2019-03-01 0

    WILSON CHARLES CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2019-03-01 0

    FMR LLC

    • SEE REMARK 1
    		 No longer subject to file 2018-04-03 0

    FIL LTD

    • SEE REMARK 1
    		 No longer subject to file 2018-04-03 0

    ATLAS VENTURE FUND IX, L.P.

    ATLAS VENTURE ASSOCIATES IX, L.P.

    ATLAS VENTURE ASSOCIATES IX, LLC

    • 10% Owner
    		 3,361,535 2018-04-03 0

    SCHULKE RYAN CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    • 10% Owner
    		 9,524,537 2018-03-29 0

    STAMOULIS CHRISTIANA PRESIDENT & C.F.O.

    • Officer
    		 0 2018-03-28 0

    CONLIN MATTHEW PRESIDENT

    • Officer
    • Director
    • 10% Owner
    		 8,695,020 2018-03-20 0

    DELL JEFFREY ALAN CHIEF INFORMATION OFFICER

    • Officer
    		 92,426 2018-02-15 0

    BRAUSER MICHAEL

    • Director
    		 7,082,128 2018-02-13 0

    DUBNER DEREK CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 1,214,512 2017-12-14 0

    MACLACHLAN DANIEL CHIEF FINANCIAL OFFICER

    • Officer
    		 371,911 2017-12-14 0

    FROST PHILLIP MD ET AL

    FROST GAMMA INVESTMENTS TRUST

    • Director
    • 10% Owner
    • JOINT FILER
    		 18,751,541 2017-12-08 0

    JORDAN HARRY BAKER III CHIEF OPERATING OFFICER

    • Officer
    		 210,000 2017-03-22 0

    SWAYMAN ROBERT

    • Director
    		 103,130 2017-01-20 0

    FRIED ROBERT N

    • Director
    		 390,671 2016-11-07 0

    3M CO

    VENTURA ACQUISITION CORP

    • 10% Owner
    		 64,921,969 2010-10-08 0

    HSIEH MING CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    • 10% Owner
    		 15,259,965 2010-05-13 0

    KIM PAUL CHIEF FINANCIAL OFFICER

    • Officer
    		 449,965 2007-08-15 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    FERRANTE KAREN JEAN - Director

    		2023-10-03 16:51:38 -0400 2023-10-02 A 2,345 a 2,345 direct

    ROS MATTHEW - Director

    		2023-10-03 16:56:48 -0400 2023-10-02 A 2,170 a 2,170 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    COGENT BIOSCIENCES INC COGT 2023-11-27 22:15:04 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 21:45:04 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 21:15:03 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 20:45:04 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 20:15:05 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 19:45:04 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 19:15:04 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 18:45:05 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 18:15:03 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 17:45:04 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 17:15:03 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 16:45:04 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 16:15:03 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 15:45:04 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 15:15:03 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 14:45:03 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 14:15:04 UTC 4.849 0.471 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 13:45:04 UTC 3.7036 1.6164 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 13:15:04 UTC 3.7036 1.6164 1700000
    COGENT BIOSCIENCES INC COGT 2023-11-27 12:45:04 UTC 3.7036 1.6164 1700000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments